Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bornaplate is a biosimilar of romiplostim developed by Borna Biopharma. It is a recombinant fusion protein (peptibody) consisting of an Fc antibody fragment fused to peptide sequences that bind to and activate the thrombopoietin (TPO) receptor. By mimicking endogenous thrombopoietin, Bornaplate stimulates the proliferation and differentiation of megakaryocytes and their progenitors in the bone marrow, thereby increasing platelet production. It is approved for the treatment of chronic immune thrombocytopenic purpura (ITP) in adult patients who have had an insufficient response to other treatments such as corticosteroids, immunoglobulins, or splenectomy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bornaplate.